The government wants to classify CBD herbs as narcotics. What does this mean for Polish users?

The idea of classifying CBD flower as a narcotic has been a recurring topic in Polish public debate since 2018. Each time, it sparks a storm among consumers, industrial hemp growers, and owners of hemp shops. According to data from the Cannabis Market Information Center (CIRK) from 2024, there are over 1,200 stationary and e-commerce shops in Poland offering CBD products, and the number of flower users is estimated by industry estimates to reach 300-450 thousand adults.

What exactly is on the legislative table today? Could CBD flower actually end up on the list of narcotics alongside amphetamines and heroin? What legal shields do EU directives and the CJEU ruling in the Kanavape case provide us? This guide explains the history of regulations, the current legal status in 2026, the arguments of both sides of the dispute, and what you should realistically do as a consumer or entrepreneur if the regulations change.

The short answer: is CBD flower legal in Poland today?

Yes. As of April 25, 2026, hemp flower containing less than 0.3% THC remains legal in Poland for trade, possession, and consumption as a product derived from industrial hemp (the Act of July 29, 2005, on counteracting drug addiction, ISAP). Proposals for tightening regulations return cyclically, but none have been passed so far.

What is changing dynamically?

The main change is in the way law enforcement and health authorities interpret the regulations. Despite the unchanged content of the law, there are instances of inspections of hemp shops ending with the seizure of goods, and courts often dismiss such cases after several months (Helsinki Foundation for Human Rights, report 2023). This creates a state of legal uncertainty, where a consumer legally purchases a product, but the risk of police seizure is real.

What is the scale of the potential ban?

The latest projects from 2024 proposed two scenarios. The first is the complete removal of the "hemp fiber" category from the anti-drug law and subjecting all cannabis flowers to narcotic regulations. The second is to restrict the sale of CBD flower exclusively to pharmacies, by prescription, as a medicinal product. Each of these would mean the end of the retail market in its current form.

CBD flower <0.3% THC remains legal in Poland in 2026 according to the anti-drug law (Dz.U. 2005 nr 179 poz. 1485, ISAP). The recurring proposals to tighten regulations have not been passed, but they create a state of legal uncertainty, where inspections of cannabis shops lead to seizures of goods that end in dismissals in courts.

Where did the proposal for a ban come from? Historical background of hemp regulations in Poland

Polish hemp regulations have evolved over two decades. According to an analysis by the Polish Drug Policy Network (2023), the number of police interventions related to marijuana increased from 14,000 in 2005 to over 70,000 in 2022, despite CBD products being introduced to the market specifically to reduce this number through legal alternatives.

The Act of July 29, 2005, the foundation of the system

The Act on Counteracting Drug Addiction (Dz.U. 2005 nr 179 poz. 1485) established the core of drug law in Poland (ISAP, 2005). It introduced the concepts of "hemp other than fiber" (prohibited) and "fiber hemp" (permitted for cultivation for industrial purposes with THC content below 0.2%, raised in 2022 to 0.3%). This dual classification still determines what is a narcotic and what is an agricultural product.

Amendment 2017, medical marijuana

On November 1, 2017, an amendment came into force allowing the prescription of hemp flower for medical purposes (Dz.U. 2017 poz. 1458). According to data from the Supreme Pharmaceutical Chamber, in 2024, approximately 145,000 prescriptions for medical marijuana were filled in Poland, compared to 1,800 in 2018. This represents an over 80-fold increase in seven years, changing the perception of hemp in the Polish healthcare system.

Raising the THC limit to 0.3% in 2022

On May 7, 2022, an amendment came into force raising the allowable THC limit in industrial hemp from 0.2% to 0.3% (Dz.U. 2022 poz. 764). This harmonized Polish law with EU Regulation 2021/2115 regarding CAP subsidies. As a result, farmers can cultivate a wider range of strains, and CBD producers can offer flowers with a more pronounced terpene profile.

Why does the "narcotization" of dry cannabis return cyclically?

Recurring proposals for a ban have a common denominator: they usually appear 6-8 months after an increase in the visibility of CBD shops in the public space. This happened in 2018 (opening of the first chains), 2021 (e-commerce boom during the pandemic), and 2024 (outdoor campaigns). This correlation suggests that the stimulus is not medical data, but the perception of the "normalization" of the market by decision-makers.

The Polish cannabis regulation system is based on the law of July 29, 2005, on counteracting drug addiction (ISAP, Dz.U. 2005 nr 179 poz. 1485), which distinguishes "fiber" cannabis (THC <0.3%) and "other than fiber". Amendments from 2017 (medical marijuana) and 2022 (THC limit) eased the regime, while current proposals to ban CBD flower would reverse this trend.

What exactly do the latest proposed changes entail?

According to an analysis of legislative proposals available at the Government Legislative Center and expert opinions from the Helsinki Foundation for Human Rights (2024), key proposals revolved around three solutions. Each has different consequences for the market, and none have yet come into force. As of April 25, 2026, the status quo remains.

Option 1: classifying flower as a Group I-N narcotic

The most restrictive option would foresee placing hemp flowers (regardless of THC content) on the list of Group I-N narcotics. This is the same regime as for heroin and cocaine. The consequence would be that possession of CBD flower could lead to up to 3 years of imprisonment (Article 62(1) of the Act on Counteracting Drug Addiction). Industry lawyers indicate that such an option would conflict with EU law.

Option 2: pharmacy-only sales by prescription

The second scenario proposed moving CBD flower to the category of medicinal products, available only in pharmacies by prescription. According to data from the Supreme Pharmaceutical Chamber (2024), a gram of medical marijuana costs the patient 65-95 PLN, while CBD flower in hemp shops ranges from 8-25 PLN per gram. This significant price difference would effectively restrict access for most current consumers.

Option 3: tightening advertising and online sales

The mildest option would maintain the legality of CBD flower but would introduce a ban on external advertising, online advertising, and limit sales to physical stores with age verification. The model is based on Dutch coffee shops and German regulations passed in 2024. This is the option that the industry considers most likely and has been the subject of industry consultations since 2023.

The CBD industry's position on the options

In a survey conducted in March 2025 among 87 Polish hemp shops (convenience sample, data from u Bucha), 78% of respondents indicated option 3 as acceptable while maintaining the possibility of online sales with age verification. Option 2 (pharmacies) was rejected by 94%, and option 1 (ban) by 100%. The dominant concern is the lack of a transition period longer than 12 months.

The latest proposed changes include three options: a complete ban (Group I-N), pharmacy sales by prescription, or tightening advertising (source: Helsinki Foundation for Human Rights, report 2024). According to an industry survey from March 2025 (87 shops), 78% of entrepreneurs accept option 3, but 100% reject the full criminalization of CBD flower.

How does EU law protect the CBD market? The Kanavape ruling and Novel Food

EU law is the strongest shield for the CBD industry against national bans. The landmark CJEU ruling of November 19, 2020, in the C-663/18 Kanavape case established that a member state cannot prohibit the sale of CBD legally produced in another EU country unless it proves that it poses a risk to public health (EUR-Lex, 2020).

What follows from the Kanavape C-663/18 ruling?

The Court ruled that CBD is not covered by the 1961 UN Single Convention on Narcotic Drugs, as it does not have psychoactive effects or harmful effects at normal doses. A ban on the marketing of CBD produced legally in another member state violates Article 34 TFEU (free movement of goods). An exception requires hard scientific evidence, which the French legislator did not provide.

Novel Food status and EFSA opinion

EU Regulation 2015/2283 on novel food (EUR-Lex, 2015) requires authorization for each new food ingredient. CBD has been listed in the Novel Food catalog since January 2019, and in its opinion from June 2022, EFSA suspended the assessment of 19 applications, citing gaps in data regarding bioaccumulation, liver impact, and reproductive toxicity (EFSA Journal, 2022).

Does EFSA's position apply to CBD flower?

Not directly. EFSA's opinion concerns CBD as a food ingredient (oils, capsules, sweets), not hemp flower for smoking, vaporization, or aromatherapy. Legally, CBD flower is classified as an agricultural or collectible product, not food. This is a significant distinction used by the industry in its dispute with the regulator.

WHO and ECDD position

The WHO Expert Committee on Drug Dependence (ECDD) in a critical review from 2018 stated that "pure CBD does not exhibit potential for dependence or significant health effects" and does not require inclusion in international drug control conventions (WHO, 2018). This recommendation was used in the Kanavape ruling as evidence of the lack of health risk.

The CJEU ruling C-663/18 Kanavape (EUR-Lex, 2020) prohibited EU states from blocking CBD legally produced in another Community country if there is no hard evidence of health risk. This serves as a shield for the Polish CBD industry, reinforced by the ECDD WHO report (2018), which states that pure CBD does not exhibit potential for dependence.

Arguments of advocates for stricter regulations

Proponents of the CBD flower ban operate on three main theses: public health protection, visual similarity to recreational marijuana, and the issue of THC content labeling. According to a CBOS study "Attitudes Towards Drugs" (2024), 41% of Poles cannot distinguish CBD from THC, which advocates for stricter regulations use as evidence of social misinformation.

Public health argument

Advocates point to EFSA's 2022 opinion on gaps in safety data for CBD, FDA warnings about CBD interactions with antiepileptic and anticoagulant medications, and case studies of liver disorders at high doses. They argue that trading outside the control of a doctor and pharmacist poses a risk that consumers cannot assess without professional knowledge.

Visual similarity to marijuana argument

The second argument concerns the difficulty of distinguishing CBD flower from marijuana "by eye". According to a report from the National Police Headquarters (2023), the number of interventions in which officers seized cannabis flower that later turned out to be legal CBD increased from 1,200 in 2020 to over 4,800 in 2023. Each such seizure requires laboratory tests costing 280-450 PLN and blocks the police for several hours.

THC labeling argument

The third argument concerns the precision of THC content labeling in flower. According to consumer tests by the Federation of Consumers (2023), out of 47 tested samples of CBD flower from Polish shops, 9 (19%) exceeded the allowable limit of 0.3% THC. The distribution of THC in the hemp plant is uneven, and a batch compliant with the COA analytical certificate may exceed the norm at the level of a single flower.

Weakness of the health argument

The health argument is the weakest link in the pro-ban narrative. Iffland and Grotenhermen in their review of CBD safety publications (PubMed, 2017) stated that "CBD is well tolerated, and its safety profile is favorable even at high doses up to 1500 mg per day". No serious adverse effects were reported at typical consumer doses (5-50 mg).

Proponents of the ban point to health protection (gaps in EFSA data, 2022), the problem of distinguishing CBD dry cannabis from marijuana (4,800 police interventions in 2023, KGP), and the imprecision of THC labeling (19% of samples above the norm, Consumer Federation 2023). The health argument is weakened by the meta-analysis by Iffland & Grotenhermen (PubMed, 2017) confirming the good safety profile of CBD.

Arguments against the ban

The CBD industry, medical experts, and consumer organizations present arguments based on economics, scientific research, and the right to choose. According to a report from the National Support Center for Agriculture (2024), the area of industrial hemp in Poland exceeded 3,700 hectares in 2024, and the value of the CBD market is estimated at 250-400 million PLN annually. A ban would mean the destruction of this ecosystem.

Economic argument

The CBD industry generates jobs in three segments: agriculture (cultivation), processing (extraction, production), and retail. According to estimates from the Polish Hemp Chamber (2024), the sector directly employs 6-8 thousand people, and indirectly (suppliers, marketing, logistics) another 12-15 thousand. A complete ban on flower would eliminate about 35-40% of industry turnover and require the requalification of thousands of entities.

Scientific argument

The second argument is based on the growing body of scientific evidence confirming the safety and therapeutic potential of CBD. WHO ECDD (2018), Iffland & Grotenhermen (2017), and opinions from the European Cannabis Research Association (EICA) consistently indicate that CBD has no addictive potential or psychoactive effects. Classifying it as a drug would be inconsistent with the current scientific consensus.

Right to choose argument

The third argument appeals to the autonomy of the adult consumer. According to a CBOS study "Attitudes Towards Cannabis" (2024), 67% of adult Poles support the availability of CBD products without a prescription, and 54% support the legalization of recreational marijuana. A ban on CBD flower would go against social expectations and repeat the mistakes of the "war on drugs," which, according to the Global Commission on Drug Policy report (2023), did not reduce the consumption of illegal substances.

What do CBD shop customers say?

In conversations with customers at u Bucha, the most frequently mentioned motivations for purchasing CBD flower are: evening relaxation (38%), stress reduction (27%), sleep support (19%), and relief from minor discomfort (16%, internal data 2025). Only 4% of customers declare a "recreational" purpose in the sense of seeking an intoxicating effect, which CBD does not produce. The profile of a typical buyer is an adult aged 30-55 from a city with over 100,000 residents.

Opponents of the ban point to 6-8 thousand jobs directly and 12-15 thousand indirectly (Polish Hemp Chamber, 2024), scientific consensus on the safety of CBD (WHO ECDD 2018; Iffland & Grotenhermen, PubMed 2017), and social support of 67% of Poles for over-the-counter availability of CBD (CBOS, 2024). A ban would mean the disappearance of 35-40% of the CBD industry's turnover.

What would tightening regulations mean for ordinary users?

For CBD users, potential changes in regulations mean three real scenarios: restricted access, increased prices, and the need to change the product format. According to an online survey by the Cannabis Consumers Association (2024, n=2,340 respondents), 71% of CBD flower users declared that in the event of a ban, they would switch to oils or capsules, 18% would limit consumption, and 11% would purchase from illegal sources.

CBD oils as the first alternative

CBD oils (full spectrum, broad spectrum, isolate) are the most popular alternative to flower. The advantage is precise dosing of drops, a long shelf life (12-24 months), no inhalation, and discreet consumption. The downside is the time it takes for effects to occur (30-90 minutes for oral administration, 15-30 minutes for sublingual). A 5-10% oil is sufficient for most consumers who previously used CBD flower.

SOOL CBD 5% (76 PLN) and SOOL CBD 10% (99 PLN) are examples of full spectrum oils from Polish hemp with COA certification. guide on concentrations and dosing

CBD and CBG capsules

Capsules are another alternative, especially for those who do not tolerate the taste of oil. A standardized dose (usually 10-25 mg per capsule) makes it easier to control and maintain a consumption diary. Cannova CBG 15% (240 PLN) is an example of a high-concentration CBG oil, a cannabinoid that differs from CBD in its action profile, popular among those seeking an energizing effect during the day.

CBD e-liquids for vaporization

CBD e-liquids allow for a quick effect known from vaporizing flower (1-5 minutes) without the need to have the flower itself. The legal status of e-liquids is more stable, as they are regulated by the Act on Health Protection against the Consequences of Tobacco Use. The downside is lower bioavailability than with flower vaporization and the need to have a device.

What about the current flower? Mars Dry CBD 9% and similar products

As long as the law is not changed, CBD flower remains legal for purchase and possession. Mars Dry CBD 9% (59 PLN) is an example of a product in a concentration range popular among consumers who appreciate a distinct terpene profile. Purchasing with an invoice, COA certificate, and label "fiber hemp" provides additional security in case of inspections.

According to a survey by the Cannabis Consumers Association (2024, n=2,340), 71% of CBD flower users would switch to oils or capsules in the event of a ban. Full spectrum oils, standardized capsules (10-25 mg), and CBD e-liquids are the three most popular alternatives offering different action profiles, dosing, and onset times.

What consequences threaten the industry and entrepreneurs?

For entrepreneurs, the CBD industry is not a hobby but a workplace and an investment. According to data from the Central Register and Information on Economic Activity (CEIDG), by the end of 2024, there were over 4,200 sole proprietorships registered with PKD 47.78.Z (other retail sale), where hemp products are the main goods. A ban on flower would hit them the hardest.

Physical stores and e-commerce

Hemp shops are the most visible part of the industry. According to CIRK (2024), there are over 1,200 stationary shops and about 800 e-commerce shops operating in Poland. The average trade margin on flower is 35-55%, significantly higher than on oils (25-35%). Eliminating flower from the assortment reduces profitability by 15-25 percentage points, which usually means the breakeven point for small shops.

Industrial hemp growers

The area of fiber hemp in Poland exceeded 3,700 ha in 2024 (National Support Center for Agriculture, 2024) compared to 1,800 ha in 2020, which is an increase of over 100% in four years. Introducing a ban on CBD flower would mean a shift in cultivation direction from "flowering" varieties (for CBD production) to technical fiber or seeds, where the price is 5-10 times lower, and CAP subsidies do not cover the losses.

Producers of oils and extracts

Polish companies producing CBD oils have transitioned from single home extractions to certified GMP laboratories between 2020 and 2024. Investments in CO2 equipment and HPLC analytics amount to millions of PLN. A ban on flower would reduce the domestic raw material base, forcing producers to import extracts from the EU (Czech Republic, Germany, Netherlands), which would raise costs by 20-40%.

Export and regional competitiveness

The Polish CBD sector is increasingly exporting to Germany, the Czech Republic, and Scandinavian countries. According to GUS (2024), the export of hemp products from Poland increased from 38 million PLN in 2020 to 187 million PLN in 2023. A domestic ban would reduce production scale and price competitiveness of Polish producers against Czech and German competitors, who operate in a more stable legal environment.

Tightening regulations would hit 1,200 stationary shops, 800 e-commerce (CIRK, 2024), 4,200 businesses in PKD 47.78.Z (CEIDG, 2024), and growers with 3,700 hectares of industrial hemp (KOWR, 2024). The export of hemp products increased from 38 million PLN (2020) to 187 million PLN (2023, GUS), and a domestic ban would reduce this momentum.

Practical advice: where and how to safely buy CBD flower?

In a state of legal uncertainty, three elements are key: a legal source of purchase, product documentation, and knowledge of your rights. According to a report from the Federation of Consumers (2023), one in five samples of CBD flower from anonymous online purchases exceeds the 0.3% THC limit. Choosing a verified seller minimizes this risk.

Check the COA certificate

The Certificate of Analysis (COA) is a laboratory document confirming the cannabinoid content in a given batch of flower. It should include: the name and address of the laboratory, batch number, sample collection date, CBD and THC content in percentages, terpene profile, and tests for heavy metals and pesticides. Reputable laboratories in Poland include J.S. Hamilton, Eurofins, Argenta.

Keep the invoice or receipt

An invoice or receipt is your legal protection in case of a police check. They should include the product name with the note "hemp", batch number, purchase date, and seller's information. In case of seizure, you can demonstrate a legal source and request the return of the goods after laboratory tests. The Helsinki Foundation for Human Rights (2023) recorded a discontinuation of proceedings in 78% of such cases.

Avoid flower from anonymous sources

Flower offered at markets, in pawn shops, or on social media without a physical store and COA certificate is the highest risk. It may contain THC above the norm, mold, pesticides, or may even be marijuana offered under the guise of CBD. A price significantly below market value (below 6-7 PLN per gram) is a warning sign.

Buy from sellers with transparent documentation

Reputable sellers publish COA for each batch, offer VAT invoices (not just receipts), have a clear return policy (according to consumer law, 14 days), and respond to inquiries about the source of raw materials. The hemp shop u Bucha is one of the Polish sellers meeting these criteria, but the market also offers several dozen other trustworthy entities. detailed guide on certificates

A safe purchase of CBD flower requires a COA certificate from a reputable laboratory (J.S. Hamilton, Eurofins, Argenta), an invoice with the note "hemp", and avoiding anonymous sources. According to the Helsinki Foundation for Human Rights (2023), in 78% of cases of seizure of legal flower with documentation, the cases are dismissed by the court.

Activism and the industry's voice: who is fighting for the status quo?

The Polish hemp activism scene has been organizing for over a decade. According to data from the Public Opinion Research Center (2024), 67% of adult Poles support the availability of CBD without a prescription, but translating this majority into concrete policy requires organization. Key roles are played by petitions, industry lobbying, and public consultations. The Cannabis Liberation March (held annually since 2001) gathers 5,000 to 15,000 participants each year.

Hemp Confederation and political parties

The Hemp Confederation and other pro-reform formations (including Razem, Third Way with individual politicians) systematically submit amendments to legislative proposals. According to data from the Sejm, in the 2023-2027 term, 17 amendments concerning hemp were submitted, of which 4 directly concerned the status of CBD. The effectiveness is low, but the presence of the topic on the parliamentary agenda is increasing.

Polish Hemp Chamber and industry organizations

The Polish Hemp Chamber, the Association of Hemp Growers and Processors, and CIRK represent the interests of the industry in public consultations and in the media. Their activities include opinions on RCL projects, market reports (cited in this article), training for police and judges, and informational campaigns. They are usually the first to detect planned legislative changes and alert the industry.

Citizen petitions and public consultations

Every citizen has the right to submit a petition to the Sejm, Senate, or Ministry of Health (Act of July 11, 2014, on petitions). Anyone and any organization can participate in public consultations of legislative proposals. According to RCL data, attendance at consultations regarding hemp projects increased from 47 positions (2018) to over 380 (2024). This is a real path to influence the final shape of regulations.

How can consumers realistically help?

The most effective consumer actions are: tracking public consultations at RCL and submitting your own positions, supporting industry organizations through membership or donations, writing to your MPs (personal emails have more impact than mass forms), and sharing reliable scientific research on social media. One petition with 50,000 signatures has more power than 50,000 comments online.

The Polish hemp activism scene includes the Hemp Confederation, the Polish Hemp Chamber, CIRK, and citizen petitions (the 2014 petition law). Attendance at public consultations regarding hemp projects increased from 47 positions (2018) to over 380 (2024, RCL data), and 67% of adult Poles support the availability of CBD without a prescription (CBOS, 2024).

Forecasts and scenarios for 2026-2028

Experts indicate three most likely scenarios for the development of CBD regulations in Poland over the next two years. According to an analysis by the Foundation for Social Initiatives (2025), the probability of a complete ban on CBD flower is estimated at 12-18%, the probability of regulations like "age-verified store" at 55-65%, and the status quo at 20-30%.

Scenario 1: "German-style" regulation (most likely)

The most likely scenario is to model after the German Cannabisgesetz of 2024, partially legalizing hemp with advertising restrictions and mandatory age verification. The Polish version would maintain the legality of CBD flower but: ban outdoor and digital advertising, age verification 18+, ban sales near schools (250 m), and require COA for each batch. Vacatio legis of 12-24 months.

Scenario 2: status quo with minor adjustments

The second scenario is the maintenance of current regulations with minor clarifying adjustments (definition of "hemp", COA requirements, administrative penalties for exceeding THC). It is favored by political paralysis, lack of consensus within the ruling coalition, and strong economic lobbying from the industry. This variant is best for current consumers but maintains a state of legal uncertainty.

Scenario 3: complete ban or pharmacy bottleneck (least likely)

The third scenario is a complete ban on CBD flower or its transfer to pharmacies by prescription. The probability is low due to conflict with EU law (Kanavape ruling), industry resistance, and social support for the availability of CBD. It could only happen in the event of a sudden media crisis (e.g., a high-profile poisoning case, even if the causal link to CBD is questionable) or a political decision that does not consider the consequences.

What determines the direction of changes?

The decisive factors are not medical or scientific but political. Three variables carry the most weight: the position of the Ministry of Health (usually restrictive) versus the Ministry of Agriculture (usually liberal), the strength of industry lobbying, and the attitude of the new EU authorities in Brussels. The parliamentary elections in 2027 and the next term of the European Commission are key dates to watch.

According to the Foundation for Social Initiatives (2025), "German Cannabis Act" type regulation (age verification 18+, outdoor advertising ban, mandatory COA) has a 55-65% probability. Status quo, 20-30%, complete ban, 12-18%. The decision depends on the dynamics of the Ministry of Health, the Ministry of Agriculture, the industry, and the legal environment of the EU.

What to do here and now? A checklist in case of changes

Regardless of the scenario, it is worth being prepared. According to a survey by the Polish Hemp Chamber (2025), only 23% of hemp shops have an action plan in case of a complete ban on flower, and 41% do not actively monitor legislative changes. This section summarizes practical steps for consumers and entrepreneurs.

Checklist for consumers

• Buy only from shops with an invoice and COA for each batch.
• Keep purchase documents (invoice, COA) together with the product for at least 2 years.
• Keep the flower in its original packaging with the label "hemp".
• Do not travel with CBD flower to countries that do not accept it (Slovakia, Lithuania).
• Subscribe to industry and consumer organization newsletters to stay updated.
• Consider alternatives (oils, capsules, e-liquids) as a supplement to your repertoire.
• In case of a police inspection, remain calm, show your documents, and do not agree to waive the receipt of seized goods.

Checklist for entrepreneurs

• Monitor projects at RCL and public consultations (at least once a week).
• Diversify your assortment; flower should not account for more than 40-50% of turnover.
• Build relationships with a lawyer specializing in pharmaceutical and drug law.
• By joining an industry organization (PIK, CIRK), participate in consultations.
• Build a customer base in your newsletter to quickly communicate changes in your assortment.
• Prepare a Plan B for 12 and 24 months in case of tightened regulations.
• Invest in quality certificates (COA, GMP, ISO 22000, cosmetic CPNP) to increase credibility.

Where to get reliable information about changes?

The most reliable sources are: Government Legislative Center (RCL, projects), Sejm website (sejm.gov.pl), Ministry of Health (gov.pl/web/zdrowie), Chief Sanitary Inspectorate (gov.pl/web/gis), and analyses from the Helsinki Foundation for Human Rights (hfhr.pl). General media should be listened to critically, as they often simplify or dramatize the topic.

According to the Polish Hemp Chamber (2025), only 23% of CBD shops have a plan in case of a complete ban on flower, and 41% do not monitor legislative changes. Consumers should keep purchase documents and COA for 2 years, while entrepreneurs should diversify their assortment (flower max 40-50% of turnover) and monitor RCL at least weekly.

FAQ: frequently asked questions about the legal status of CBD flower

Is CBD flower legal in Poland in 2026?

Yes. Hemp flower containing less than 0.3% THC remains legal in Poland in 2026 as a product derived from industrial hemp according to the Act of July 29, 2005, on counteracting drug addiction (Dz.U. 2005 nr 179 poz. 1485, ISAP). Proposals to tighten regulations are recurring, but none have been passed. The status quo maintains the legality of purchase, possession, and consumption for adults.

What are the penalties for possessing illegal hemp flower?

According to Article 62, paragraph 1 of the Act on Counteracting Drug Addiction, possession of narcotic substances is punishable by imprisonment for up to 3 years, and in the case of a significant amount, from 6 months to 8 years (Article 62, paragraph 2). CBD flower <0.3% THC is not a narcotic substance, so these regulations do not apply to it. Exceeding the THC limit changes the product's status.

Can I transport CBD flower to another EU country?

It depends on the destination country. According to the CJEU ruling C-663/18 Kanavape (EUR-Lex, 2020), EU states cannot prohibit CBD legally produced in another Community country without evidence of health risk. However, in practice, Slovakia, Lithuania, and some regions of Spain maintain restrictions. Always check current local regulations on embassy websites before traveling.

How to distinguish legal CBD flower from marijuana?

Exclusively through laboratory testing. Visually and by smell, CBD flower often does not differ from recreational marijuana, as it comes from the same species Cannabis sativa L. The only objective evidence is the COA analytical certificate from a reputable laboratory (e.g., J.S. Hamilton, Eurofins, Argenta) confirming THC content below 0.3%. A home "smell test" is not reliable.

Will CBD show up on a drug test at work or on the road?

A standard immunological drug test detects THC metabolites, not CBD. However, CBD flower <0.3% THC contains trace amounts of THC, which can accumulate in the body with intensive and prolonged consumption and yield a positive result. According to a study by Spindle et al. (2020, JAMA), the risk of a false positive test after high doses of full-spectrum CBD is about 50% in the first 24 hours.

Does CBD have psychoactive effects?

Not in the classical sense. The WHO ECDD in its critical review from 2018 stated that "pure CBD does not exhibit potential for addiction or significant health effects" (WHO, 2018). CBD does not induce euphoria, hallucinations, or cognitive impairment characteristic of THC. However, it may have a relaxing effect, which is sometimes inaccurately described as "psychoactive".

What is the difference between CBD flower and CBD oil?

In terms of administration, bioavailability, and duration of action. Hemp flower contains a full spectrum of cannabinoids and terpenes in their natural proportions, and when vaporized, it acts within 1-5 minutes with a bioavailability of 30-50%. Oil is a CBD extract dissolved in a fatty carrier, and when taken sublingually, it acts within 15-30 minutes with a bioavailability of 6-20%, but lasts longer (4-8 hours vs. 2-4 hours for flower).

What should I do if the police stop me with legal CBD flower?

Stay calm and present your purchase documents (invoice, COA, label "hemp"). The officer may seize the goods for laboratory testing. According to the Helsinki Foundation for Human Rights (2023), in 78% of such cases, the matter ends with discontinuation after confirming THC <0.3%. You can demand the return of the goods or compensation if the seizure was unfounded.

Will tightening regulations also affect CBD oils?

Less likely than in the case of flower. CBD oils are usually classified as cosmetics, supplements, or Novel Food products (EFSA status suspended since 2022, EFSA Journal 2022), and not as products from hemp flowers. Polish draft bans focus on flower as "visually similar to marijuana", while oils do not raise the same concerns.

Where to track current changes in the law?

The most reliable sources are the Government Legislative Center (rcl.gov.pl), the Sejm website (sejm.gov.pl), the Ministry of Health (gov.pl/web/zdrowie), the Chief Sanitary Inspectorate (gov.pl/web/gis), and analyses from the Helsinki Foundation for Human Rights (hfhr.pl). It is also worth following newsletters from the Polish Hemp Chamber and CIRK. Updates from official sources are immediate, while updates from industry media take 24-72 hours.

Summary: status as of April 25, 2026, and what next

The idea of classifying CBD flower as a drug regularly resurfaces in the Polish debate, but the legal status as of April 25, 2026, remains unchanged: hemp flower with <0.3% THC is legal for trade, possession, and consumption as a product from industrial hemp. The Act of July 29, 2005, on counteracting drug addiction (ISAP) still forms the foundation of the system, and the CJEU ruling C-663/18 Kanavape (EUR-Lex, 2020) creates a significant shield against unilateral national bans.

Of the three most likely scenarios for 2026-2028, the 'German-style' regulation dominates (55-65%, age verification, outdoor advertising ban, mandatory COA), with the status quo in second place (20-30%) and a complete ban in third (12-18%). Consumers should today rely on trustworthy purchasing sources (invoice, COA, stores with transparent documentation), while entrepreneurs should diversify their offerings and actively monitor legislative changes. Legal support comes from organizations such as the Helsinki Foundation for Human Rights and the Polish Hemp Chamber.

We encourage you to follow official announcements from the Ministry of Health, the Chief Sanitary Inspectorate, and the Government Legislative Center, as well as to actively participate in public consultations. These truly shape the final form of regulations. guide on choosing concentrations

This material is for informational and educational purposes only and does not constitute legal or medical advice. The regulatory status may change. In specific legal situations, consult a lawyer specializing in pharmaceutical or criminal law. CBD is not a medicine or therapeutic agent in the sense of pharmaceutical law.